NYSEMKT: NSRXNasus Pharma Ltd Stock
$3.62+0.42 (+13.13%)
Updated Aug 14, 2026
NSRX Price
$3.62
Fair Value Price
N/A
Market Cap
$32.64M
52 Week Low
$1.98
52 Week High
$9.99
P/E
-5.03x
P/B
11.79x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$5.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.81
Operating Cash Flow
-$5M
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NSRX's potential to beat the market
- NSRX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
NSRX
RankedUnranked of 16
RankedUnranked of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $63.83 | A | |
| $1,180.16 | A | |
| $249.46 | B |
Be the first to know about important NSRX news, forecast changes, insider trades & much more!
NSRX News
Overview
Due Diligence Score
–
Industry Average (34)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NSRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NSRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NSRX is poor value based on its book value relative to its share price (11.79x), compared to the US Drug Manufacturers - General industry average (7.84x)
P/B vs Industry Valuation
NSRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NSRX due diligence checks available for Premium users.
Valuation
NSRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.03x
Industry
37.98x
Market
15.95x
NSRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.79x
Industry
7.84x
NSRX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NSRX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
NSRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$5.0M
Liabilities
$2.2M
Debt to equity
0.81
NSRX's short-term assets ($4.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NSRX's short-term assets ($4.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NSRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NSRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NSRX vs General Drug Manufacturer Stocks
Nasus Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.